YOLFTbeta
41

Bioptik Technology

4161 · TWO · Healthcare / Medical Devices

20.90TWD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close20.90
Open21.00
Day Range20.80 – 21.05
52-Week Range21.20 – 29.35
Volume11.00K
Market Cap1.29B
P/E (TTM)11.83
Forward P/E0.00
EPS1.83
Dividend Yield3.23%
Beta0.26
50-Day Avg22.52
200-Day Avg23.97

About

Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also provides dietary supplements, such as capsules, gel capsules, tablets, solutions, powder sachet, jelly, and gummy; cosmetic products, including sunscreen, cream/lotion, make-up removal, shampoo, time capsule, and toner/essence; and skin care products. In addition, the company is involved in manufacturing feed, canned food, and food additive, aircraft and parts, and chemicals; wholesale and import and export trade of cosmetics raw materials, semi-finished products and finished products; cosmetics retail and wholesale; and special forestry management. Bioptik Technology Incorporation was founded in 1999 and is based in Zhunan, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Yao-Jen Tu
  • Employees0
  • HeadquartersNo. 188, Jhonghua South Road, Zhunan, Taiwan, 35057, Taiwan
  • Websitehttps://www.bioptik.com.tw

Leadership

  • Mr. Jin-Chang YangGM & Chairman of the Board
  • Mr. Yao-Jen TuChief Executive Officer
  • Qiaoyun XuFinance Division Manager & Accounting Supervisor
  • Mr. Kun Lie WuExecutive Officer

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue476.39M519.55M566.42M485.60M737.89M767.75M828.50M865.34M837.19M
Growth (%)-+9.06%+9.02%-14.27%+51.96%+4.05%+7.91%+4.45%-3.25%
Cost of Revenue361.49M393.24M417.82M402.44M574.35M590.29M588.96M597.43M593.68M
Gross Profit114.91M126.31M148.61M83.16M163.54M177.46M239.54M267.90M243.51M
Gross Margin24.12%24.31%26.24%17.12%22.16%23.11%28.91%30.96%29.09%
Operating Expense109.95M125.58M148.14M139.91M136.40M105.69M121.78M177.91M176.97M
Operating Income4.95M726.00K467.00K-56.76M27.14M71.78M117.76M89.99M66.53M
Operating Margin1.04%0.14%0.08%-11.69%3.68%9.35%14.21%10.40%7.95%
EBITDA-567.00K73.94M50.57M-19.01M64.13M105.25M152.47M155.10M125.69M
EBITDA Margin-0.12%14.23%8.93%-3.91%8.69%13.71%18.40%17.92%15.01%
Net Income-33.72M26.39M5.25M-59.99M22.59M48.50M85.71M93.57M71.19M
Net Income Margin-7.08%5.08%0.93%-12.35%3.06%6.32%10.35%10.81%8.50%
R&D50.03M57.54M68.63M50.15M48.94M58.30M71.47M75.35M75.20M
R&D as % of Total Revenue10.50%11.07%12.12%10.33%6.63%7.59%8.63%8.71%8.98%
Interest Expense09.11M9.76M8.47M7.82M9.19M11.00M9.13M7.61M
Interest Expense % of Total Revenue0.00%1.75%1.72%1.74%1.06%1.20%1.33%1.06%0.91%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.57B1.60B1.55B1.47B1.52B1.52B1.50B1.49B1.57B
Total Liabilities678.08M792.07M786.05M738.10M829.38M797.40M673.56M582.47M597.14M
Total Equity877.79M804.05M762.79M730.50M690.25M715.13M819.34M901.27M969.36M
Cash398.42M258.28M444.60M258.00M103.88M310.53M368.61M380.66M399.30M
Total Debt---640.56M685.91M662.87M523.24M--
Net Debt196.63M428.74M217.97M382.56M582.02M352.33M154.63M66.64M68.52M

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow11.02M41.83M41.03M6.57M-41.15M55.06M205.95M158.82M59.99M
Investing Cash Flow-181.67M-151.78M206.68M-132.83M-118.61M187.14M---
Financing Cash Flow98.39M-30.25M-60.96M-60.43M5.65M-35.56M-119.33M--
Capital Expenditure62.72M50.96M27.42M13.18M19.82M17.08M31.04M15.51M22.80M
Free Cash Flow-52.04M-10.11M12.51M-6.61M-60.97M37.98M174.91M143.32M37.19M
Dividends Paid50.24M24.14M24.14M28.96M14.48M14.48M-37.09M15.88M
FCF to OCF-472.26%-24.17%30.48%-100.50%148.17%68.98%84.93%90.24%61.99%
Dividend Paid to FCF-96.54%-238.72%192.94%-438.43%-23.75%38.13%-25.88%42.71%

Earnings

Report DateJun 30, 2012Sep 30, 2012Feb 27, 2013May 29, 2013Aug 28, 2013Nov 27, 2013Feb 26, 2014May 14, 2014Sep 3, 2014Dec 3, 2014Feb 25, 2015Jun 3, 2015Sep 2, 2015Dec 2, 2015Mar 2, 2016Jun 1, 2016Aug 16, 2016Nov 9, 2016Mar 1, 2017May 15, 2017Aug 9, 2017Nov 7, 2017Feb 28, 2018Apr 2, 2018Aug 13, 2018Nov 12, 2018Feb 27, 2019Apr 1, 2019Aug 28, 2019Nov 8, 2019Feb 26, 2020Jun 3, 2020Sep 2, 2020Nov 13, 2020Mar 3, 2021Jun 2, 2021Sep 1, 2021Nov 12, 2021Mar 2, 2022Jun 1, 2022Aug 31, 2022Nov 11, 2022Mar 1, 2023May 31, 2023
EPS Estimate------0.330.28------------------------------------
EPS Actual0.240.25-0.350.080.430.430.710.310.010.030.220.220.090.040.18-0.130.19-0.020.11-0.530.08-0.04-0.150.040.91-0.37-0.080.010.100.15-0.15-0.29-0.13-0.49-0.340.040.090.230.110.040.020.600.340.15
Surprise------117.03%10.71%------------------------------------
Timing-------Pre-market--------Pre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketAfter-hoursAfter-hours-After-hours----------------

Key Statistics & Ratios

Market Cap1.29B
Enterprise Value1.35B
Trailing P/E11.83
Forward P/E0.00
Price / Sales1.42
Price / Book1.34
EPS1.83
Book Value16.53
Revenue (TTM)912.86M
Gross Profit (TTM)257.09M
EBITDA98.36M
Profit Margin11.89%
Operating Margin6.15%
Return on Equity11.20%
Return on Assets2.91%
Shares Outstanding59.80M
Shares Float41.18M
Beta0.26
Dividend Yield3.23%
Dividend Rate0.70
Payout Ratio16.41%

Dividends

20261×
0.70Jul 16, 2026
20251×
0.30Aug 20, 2025
20241×
0.62Jul 16, 2024
20221×
0.25Aug 11, 2022
20211×
0.25Sep 8, 2021
20201×
0.51Jul 23, 2020
20191×
0.42Jul 31, 2019
20171×
0.12Jul 31, 2017
20161×
0.40Sep 5, 2016
20151×
0.83Jul 28, 2015

Stock Splits

  • Aug 20, 20251130.0369:1000
  • Aug 28, 20231050:1000
  • Aug 23, 20181051.27:1000
  • Sep 9, 20141147.715:1000
  • Sep 10, 20121.015:1